Cargando…

Global trends in the incidence rates of MDR and XDR tuberculosis: Findings from the global burden of disease study 2019

Purpose: The study aimed to quantify the global trends of the incidence rates of multidrug-resistant (MDR) tuberculosis (MDR-TB) and extensively drug-resistant (XDR) tuberculosis (XDR-TB). Methods: Cases, age-standardized rates (ASRs), and incidence rates of MDR-TB and XDR-TB during 2010–2019 were o...

Descripción completa

Detalles Bibliográficos
Autores principales: Bu, Qingting, Qiang, Rong, Fang, Lingyan, Peng, Xiaokang, Zhang, Hua, Cheng, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998482/
https://www.ncbi.nlm.nih.gov/pubmed/36909179
http://dx.doi.org/10.3389/fphar.2023.1156249
_version_ 1784903472637804544
author Bu, Qingting
Qiang, Rong
Fang, Lingyan
Peng, Xiaokang
Zhang, Hua
Cheng, Hua
author_facet Bu, Qingting
Qiang, Rong
Fang, Lingyan
Peng, Xiaokang
Zhang, Hua
Cheng, Hua
author_sort Bu, Qingting
collection PubMed
description Purpose: The study aimed to quantify the global trends of the incidence rates of multidrug-resistant (MDR) tuberculosis (MDR-TB) and extensively drug-resistant (XDR) tuberculosis (XDR-TB). Methods: Cases, age-standardized rates (ASRs), and incidence rates of MDR-TB and XDR-TB during 2010–2019 were obtained from the Global Burden of Disease Study 2019. The incidence trends of MDR-TB and XDR-TB were evaluated using the estimated annual percentage changes (EAPCs) in ASRs. The relationships among the ASRs of MDR-TB and XDR-TB, the MDR rate, the XDR rate, and socio-demographic index (SDI) were assessed using locally weighted regression and Pearson’s correlation coefficient. Results: The global ASR of MDR-TB on average decreased by 1.36% (EAPC = −1.36, 95% confidence interval [CI] = −2.19 to −0.52) per year whereas that of XDR-TB was stable (EAPC = 0.69, 95% CI = −0.15–1.54) during 2010–2019. The incidence trends of MDR-TB in most regions and countries were decreasing, but those of XDR-TB were increasing. People aged 35–44 and 55–64 years had the highest incidence rates for MDR-TB and XDR-TB. The MDR and XDR rates both peaked in those aged 35–44 years. Areas with higher SDI tended to have lower ASRs of MDR-TB (p < 0.001, ρ = −0.43). Conclusion: The current achievements for the incidence trends of MDR-TB and XDR-TB are insufficient. More strategies and tools need to be developed to further curb MDR-TB and XDR-TB, especially in high-risk areas and age groups, and in low SDI regions.
format Online
Article
Text
id pubmed-9998482
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99984822023-03-11 Global trends in the incidence rates of MDR and XDR tuberculosis: Findings from the global burden of disease study 2019 Bu, Qingting Qiang, Rong Fang, Lingyan Peng, Xiaokang Zhang, Hua Cheng, Hua Front Pharmacol Pharmacology Purpose: The study aimed to quantify the global trends of the incidence rates of multidrug-resistant (MDR) tuberculosis (MDR-TB) and extensively drug-resistant (XDR) tuberculosis (XDR-TB). Methods: Cases, age-standardized rates (ASRs), and incidence rates of MDR-TB and XDR-TB during 2010–2019 were obtained from the Global Burden of Disease Study 2019. The incidence trends of MDR-TB and XDR-TB were evaluated using the estimated annual percentage changes (EAPCs) in ASRs. The relationships among the ASRs of MDR-TB and XDR-TB, the MDR rate, the XDR rate, and socio-demographic index (SDI) were assessed using locally weighted regression and Pearson’s correlation coefficient. Results: The global ASR of MDR-TB on average decreased by 1.36% (EAPC = −1.36, 95% confidence interval [CI] = −2.19 to −0.52) per year whereas that of XDR-TB was stable (EAPC = 0.69, 95% CI = −0.15–1.54) during 2010–2019. The incidence trends of MDR-TB in most regions and countries were decreasing, but those of XDR-TB were increasing. People aged 35–44 and 55–64 years had the highest incidence rates for MDR-TB and XDR-TB. The MDR and XDR rates both peaked in those aged 35–44 years. Areas with higher SDI tended to have lower ASRs of MDR-TB (p < 0.001, ρ = −0.43). Conclusion: The current achievements for the incidence trends of MDR-TB and XDR-TB are insufficient. More strategies and tools need to be developed to further curb MDR-TB and XDR-TB, especially in high-risk areas and age groups, and in low SDI regions. Frontiers Media S.A. 2023-02-24 /pmc/articles/PMC9998482/ /pubmed/36909179 http://dx.doi.org/10.3389/fphar.2023.1156249 Text en Copyright © 2023 Bu, Qiang, Fang, Peng, Zhang and Cheng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Bu, Qingting
Qiang, Rong
Fang, Lingyan
Peng, Xiaokang
Zhang, Hua
Cheng, Hua
Global trends in the incidence rates of MDR and XDR tuberculosis: Findings from the global burden of disease study 2019
title Global trends in the incidence rates of MDR and XDR tuberculosis: Findings from the global burden of disease study 2019
title_full Global trends in the incidence rates of MDR and XDR tuberculosis: Findings from the global burden of disease study 2019
title_fullStr Global trends in the incidence rates of MDR and XDR tuberculosis: Findings from the global burden of disease study 2019
title_full_unstemmed Global trends in the incidence rates of MDR and XDR tuberculosis: Findings from the global burden of disease study 2019
title_short Global trends in the incidence rates of MDR and XDR tuberculosis: Findings from the global burden of disease study 2019
title_sort global trends in the incidence rates of mdr and xdr tuberculosis: findings from the global burden of disease study 2019
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998482/
https://www.ncbi.nlm.nih.gov/pubmed/36909179
http://dx.doi.org/10.3389/fphar.2023.1156249
work_keys_str_mv AT buqingting globaltrendsintheincidenceratesofmdrandxdrtuberculosisfindingsfromtheglobalburdenofdiseasestudy2019
AT qiangrong globaltrendsintheincidenceratesofmdrandxdrtuberculosisfindingsfromtheglobalburdenofdiseasestudy2019
AT fanglingyan globaltrendsintheincidenceratesofmdrandxdrtuberculosisfindingsfromtheglobalburdenofdiseasestudy2019
AT pengxiaokang globaltrendsintheincidenceratesofmdrandxdrtuberculosisfindingsfromtheglobalburdenofdiseasestudy2019
AT zhanghua globaltrendsintheincidenceratesofmdrandxdrtuberculosisfindingsfromtheglobalburdenofdiseasestudy2019
AT chenghua globaltrendsintheincidenceratesofmdrandxdrtuberculosisfindingsfromtheglobalburdenofdiseasestudy2019